nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A5—Teniposide—lymphatic system cancer	0.0841	0.201	CbGbCtD
Aripiprazole—CYP3A7—Vincristine—lymphatic system cancer	0.054	0.129	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.054	0.129	CbGbCtD
Aripiprazole—CYP3A5—Vincristine—lymphatic system cancer	0.0405	0.0969	CbGbCtD
Aripiprazole—ABCB1—Mitoxantrone—lymphatic system cancer	0.0383	0.0916	CbGbCtD
Aripiprazole—CYP3A4—Cytarabine—lymphatic system cancer	0.0333	0.0797	CbGbCtD
Aripiprazole—CYP3A4—Teniposide—lymphatic system cancer	0.0328	0.0785	CbGbCtD
Aripiprazole—ABCB1—Vincristine—lymphatic system cancer	0.0263	0.0631	CbGbCtD
Aripiprazole—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0229	0.0549	CbGbCtD
Aripiprazole—ABCB1—Methotrexate—lymphatic system cancer	0.016	0.0382	CbGbCtD
Aripiprazole—CYP3A4—Vincristine—lymphatic system cancer	0.0158	0.0378	CbGbCtD
Aripiprazole—Rash—Teniposide—lymphatic system cancer	0.000422	0.000724	CcSEcCtD
Aripiprazole—Dermatitis—Teniposide—lymphatic system cancer	0.000421	0.000724	CcSEcCtD
Aripiprazole—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00042	0.000721	CcSEcCtD
Aripiprazole—Headache—Teniposide—lymphatic system cancer	0.000419	0.00072	CcSEcCtD
Aripiprazole—Pruritus—Fludarabine—lymphatic system cancer	0.000416	0.000714	CcSEcCtD
Aripiprazole—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000416	0.000714	CcSEcCtD
Aripiprazole—Back pain—Mitoxantrone—lymphatic system cancer	0.000415	0.000712	CcSEcCtD
Aripiprazole—Leukopenia—Carmustine—lymphatic system cancer	0.000413	0.000709	CcSEcCtD
Aripiprazole—Anorexia—Bleomycin—lymphatic system cancer	0.000411	0.000706	CcSEcCtD
Aripiprazole—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00041	0.000704	CcSEcCtD
Aripiprazole—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000408	0.0007	CcSEcCtD
Aripiprazole—Anaemia—Vincristine—lymphatic system cancer	0.000407	0.000699	CcSEcCtD
Aripiprazole—Agitation—Vincristine—lymphatic system cancer	0.000404	0.000695	CcSEcCtD
Aripiprazole—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000404	0.000694	CcSEcCtD
Aripiprazole—Photosensitivity—Methotrexate—lymphatic system cancer	0.000404	0.000694	CcSEcCtD
Aripiprazole—Polyuria—Methotrexate—lymphatic system cancer	0.000404	0.000694	CcSEcCtD
Aripiprazole—Hypotension—Bleomycin—lymphatic system cancer	0.000403	0.000692	CcSEcCtD
Aripiprazole—Diarrhoea—Fludarabine—lymphatic system cancer	0.000402	0.000691	CcSEcCtD
Aripiprazole—Convulsion—Carmustine—lymphatic system cancer	0.000399	0.000686	CcSEcCtD
Aripiprazole—Hypertension—Carmustine—lymphatic system cancer	0.000398	0.000684	CcSEcCtD
Aripiprazole—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000398	0.000683	CcSEcCtD
Aripiprazole—Nausea—Teniposide—lymphatic system cancer	0.000397	0.000682	CcSEcCtD
Aripiprazole—Anaemia—Mitoxantrone—lymphatic system cancer	0.000396	0.00068	CcSEcCtD
Aripiprazole—Vertigo—Vincristine—lymphatic system cancer	0.000395	0.000679	CcSEcCtD
Aripiprazole—Hepatic failure—Methotrexate—lymphatic system cancer	0.000395	0.000678	CcSEcCtD
Aripiprazole—Leukopenia—Vincristine—lymphatic system cancer	0.000394	0.000677	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000393	0.000675	CcSEcCtD
Aripiprazole—Myalgia—Carmustine—lymphatic system cancer	0.000392	0.000674	CcSEcCtD
Aripiprazole—Chest pain—Carmustine—lymphatic system cancer	0.000392	0.000674	CcSEcCtD
Aripiprazole—Anxiety—Carmustine—lymphatic system cancer	0.000391	0.000672	CcSEcCtD
Aripiprazole—Paraesthesia—Bleomycin—lymphatic system cancer	0.000387	0.000665	CcSEcCtD
Aripiprazole—Malaise—Mitoxantrone—lymphatic system cancer	0.000386	0.000664	CcSEcCtD
Aripiprazole—Dyspnoea—Bleomycin—lymphatic system cancer	0.000384	0.00066	CcSEcCtD
Aripiprazole—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000384	0.000659	CcSEcCtD
Aripiprazole—Convulsion—Vincristine—lymphatic system cancer	0.000381	0.000655	CcSEcCtD
Aripiprazole—Hypertension—Vincristine—lymphatic system cancer	0.00038	0.000653	CcSEcCtD
Aripiprazole—Confusional state—Carmustine—lymphatic system cancer	0.000379	0.000652	CcSEcCtD
Aripiprazole—Oedema—Carmustine—lymphatic system cancer	0.000376	0.000646	CcSEcCtD
Aripiprazole—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000376	0.000645	CcSEcCtD
Aripiprazole—Decreased appetite—Bleomycin—lymphatic system cancer	0.000375	0.000644	CcSEcCtD
Aripiprazole—Myalgia—Vincristine—lymphatic system cancer	0.000375	0.000644	CcSEcCtD
Aripiprazole—Visual disturbance—Methotrexate—lymphatic system cancer	0.000374	0.000643	CcSEcCtD
Aripiprazole—Cough—Mitoxantrone—lymphatic system cancer	0.000374	0.000642	CcSEcCtD
Aripiprazole—Infection—Carmustine—lymphatic system cancer	0.000374	0.000642	CcSEcCtD
Aripiprazole—Vomiting—Fludarabine—lymphatic system cancer	0.000374	0.000642	CcSEcCtD
Aripiprazole—Convulsion—Mitoxantrone—lymphatic system cancer	0.000371	0.000638	CcSEcCtD
Aripiprazole—Rash—Fludarabine—lymphatic system cancer	0.000371	0.000637	CcSEcCtD
Aripiprazole—Dermatitis—Fludarabine—lymphatic system cancer	0.00037	0.000636	CcSEcCtD
Aripiprazole—Hypertension—Mitoxantrone—lymphatic system cancer	0.00037	0.000636	CcSEcCtD
Aripiprazole—Pain—Bleomycin—lymphatic system cancer	0.000369	0.000633	CcSEcCtD
Aripiprazole—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000368	0.000633	CcSEcCtD
Aripiprazole—Headache—Fludarabine—lymphatic system cancer	0.000368	0.000633	CcSEcCtD
Aripiprazole—Tachycardia—Carmustine—lymphatic system cancer	0.000367	0.000631	CcSEcCtD
Aripiprazole—Myalgia—Mitoxantrone—lymphatic system cancer	0.000365	0.000627	CcSEcCtD
Aripiprazole—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000365	0.000627	CcSEcCtD
Aripiprazole—Chest pain—Mitoxantrone—lymphatic system cancer	0.000365	0.000627	CcSEcCtD
Aripiprazole—Anxiety—Mitoxantrone—lymphatic system cancer	0.000364	0.000625	CcSEcCtD
Aripiprazole—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000362	0.000622	CcSEcCtD
Aripiprazole—Lethargy—Methotrexate—lymphatic system cancer	0.000362	0.000622	CcSEcCtD
Aripiprazole—Discomfort—Mitoxantrone—lymphatic system cancer	0.00036	0.000619	CcSEcCtD
Aripiprazole—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000359	0.000617	CcSEcCtD
Aripiprazole—Oedema—Vincristine—lymphatic system cancer	0.000359	0.000617	CcSEcCtD
Aripiprazole—Anorexia—Carmustine—lymphatic system cancer	0.000359	0.000616	CcSEcCtD
Aripiprazole—Infection—Vincristine—lymphatic system cancer	0.000357	0.000613	CcSEcCtD
Aripiprazole—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000355	0.00061	CcSEcCtD
Aripiprazole—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000355	0.000609	CcSEcCtD
Aripiprazole—Confusional state—Mitoxantrone—lymphatic system cancer	0.000353	0.000606	CcSEcCtD
Aripiprazole—Nervous system disorder—Vincristine—lymphatic system cancer	0.000352	0.000605	CcSEcCtD
Aripiprazole—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000352	0.000604	CcSEcCtD
Aripiprazole—Hypotension—Carmustine—lymphatic system cancer	0.000352	0.000604	CcSEcCtD
Aripiprazole—Oedema—Mitoxantrone—lymphatic system cancer	0.00035	0.000601	CcSEcCtD
Aripiprazole—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00035	0.000601	CcSEcCtD
Aripiprazole—Nausea—Fludarabine—lymphatic system cancer	0.000349	0.0006	CcSEcCtD
Aripiprazole—Infection—Mitoxantrone—lymphatic system cancer	0.000347	0.000597	CcSEcCtD
Aripiprazole—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000347	0.000596	CcSEcCtD
Aripiprazole—Shock—Mitoxantrone—lymphatic system cancer	0.000344	0.000591	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000343	0.000589	CcSEcCtD
Aripiprazole—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000342	0.000588	CcSEcCtD
Aripiprazole—Urticaria—Bleomycin—lymphatic system cancer	0.000342	0.000588	CcSEcCtD
Aripiprazole—Anorexia—Vincristine—lymphatic system cancer	0.000342	0.000588	CcSEcCtD
Aripiprazole—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000341	0.000586	CcSEcCtD
Aripiprazole—Body temperature increased—Bleomycin—lymphatic system cancer	0.000341	0.000585	CcSEcCtD
Aripiprazole—Insomnia—Carmustine—lymphatic system cancer	0.00034	0.000585	CcSEcCtD
Aripiprazole—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00034	0.000584	CcSEcCtD
Aripiprazole—Irritability—Methotrexate—lymphatic system cancer	0.000338	0.000581	CcSEcCtD
Aripiprazole—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000338	0.000581	CcSEcCtD
Aripiprazole—Paraesthesia—Carmustine—lymphatic system cancer	0.000338	0.00058	CcSEcCtD
Aripiprazole—Mood swings—Methotrexate—lymphatic system cancer	0.000336	0.000577	CcSEcCtD
Aripiprazole—Hypotension—Vincristine—lymphatic system cancer	0.000336	0.000576	CcSEcCtD
Aripiprazole—Dyspnoea—Carmustine—lymphatic system cancer	0.000335	0.000576	CcSEcCtD
Aripiprazole—Somnolence—Carmustine—lymphatic system cancer	0.000334	0.000575	CcSEcCtD
Aripiprazole—Anorexia—Mitoxantrone—lymphatic system cancer	0.000333	0.000573	CcSEcCtD
Aripiprazole—Ataxia—Methotrexate—lymphatic system cancer	0.000333	0.000573	CcSEcCtD
Aripiprazole—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000327	0.000562	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000327	0.000562	CcSEcCtD
Aripiprazole—Decreased appetite—Carmustine—lymphatic system cancer	0.000327	0.000562	CcSEcCtD
Aripiprazole—Hypotension—Mitoxantrone—lymphatic system cancer	0.000327	0.000561	CcSEcCtD
Aripiprazole—Insomnia—Vincristine—lymphatic system cancer	0.000325	0.000558	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000325	0.000558	CcSEcCtD
Aripiprazole—Paraesthesia—Vincristine—lymphatic system cancer	0.000322	0.000554	CcSEcCtD
Aripiprazole—Constipation—Carmustine—lymphatic system cancer	0.000322	0.000553	CcSEcCtD
Aripiprazole—Pain—Carmustine—lymphatic system cancer	0.000322	0.000553	CcSEcCtD
Aripiprazole—Breast disorder—Methotrexate—lymphatic system cancer	0.00032	0.00055	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000319	0.000547	CcSEcCtD
Aripiprazole—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000318	0.000545	CcSEcCtD
Aripiprazole—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000314	0.000539	CcSEcCtD
Aripiprazole—Decreased appetite—Vincristine—lymphatic system cancer	0.000312	0.000536	CcSEcCtD
Aripiprazole—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000312	0.000536	CcSEcCtD
Aripiprazole—Somnolence—Mitoxantrone—lymphatic system cancer	0.000311	0.000534	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00031	0.000533	CcSEcCtD
Aripiprazole—Feeling abnormal—Carmustine—lymphatic system cancer	0.00031	0.000533	CcSEcCtD
Aripiprazole—Fatigue—Vincristine—lymphatic system cancer	0.00031	0.000532	CcSEcCtD
Aripiprazole—Asthenia—Bleomycin—lymphatic system cancer	0.000309	0.000531	CcSEcCtD
Aripiprazole—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000308	0.000529	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000308	0.000528	CcSEcCtD
Aripiprazole—Pain—Vincristine—lymphatic system cancer	0.000307	0.000528	CcSEcCtD
Aripiprazole—Constipation—Vincristine—lymphatic system cancer	0.000307	0.000528	CcSEcCtD
Aripiprazole—Asthma—Methotrexate—lymphatic system cancer	0.000306	0.000526	CcSEcCtD
Aripiprazole—Pruritus—Bleomycin—lymphatic system cancer	0.000305	0.000524	CcSEcCtD
Aripiprazole—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000304	0.000522	CcSEcCtD
Aripiprazole—Eosinophilia—Methotrexate—lymphatic system cancer	0.000303	0.000521	CcSEcCtD
Aripiprazole—Fatigue—Mitoxantrone—lymphatic system cancer	0.000302	0.000518	CcSEcCtD
Aripiprazole—Pancreatitis—Methotrexate—lymphatic system cancer	0.0003	0.000516	CcSEcCtD
Aripiprazole—Pain—Mitoxantrone—lymphatic system cancer	0.000299	0.000514	CcSEcCtD
Aripiprazole—Constipation—Mitoxantrone—lymphatic system cancer	0.000299	0.000514	CcSEcCtD
Aripiprazole—Abdominal pain—Carmustine—lymphatic system cancer	0.000297	0.000511	CcSEcCtD
Aripiprazole—Body temperature increased—Carmustine—lymphatic system cancer	0.000297	0.000511	CcSEcCtD
Aripiprazole—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000294	0.000505	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000294	0.000504	CcSEcCtD
Aripiprazole—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000288	0.000495	CcSEcCtD
Aripiprazole—Dysuria—Methotrexate—lymphatic system cancer	0.000287	0.000492	CcSEcCtD
Aripiprazole—Neutropenia—Methotrexate—lymphatic system cancer	0.000287	0.000492	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000286	0.000491	CcSEcCtD
Aripiprazole—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000285	0.000489	CcSEcCtD
Aripiprazole—Body temperature increased—Vincristine—lymphatic system cancer	0.000284	0.000488	CcSEcCtD
Aripiprazole—Abdominal pain—Vincristine—lymphatic system cancer	0.000284	0.000488	CcSEcCtD
Aripiprazole—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000282	0.000485	CcSEcCtD
Aripiprazole—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00028	0.00048	CcSEcCtD
Aripiprazole—Urticaria—Mitoxantrone—lymphatic system cancer	0.000278	0.000477	CcSEcCtD
Aripiprazole—Hypersensitivity—Carmustine—lymphatic system cancer	0.000277	0.000476	CcSEcCtD
Aripiprazole—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000276	0.000475	CcSEcCtD
Aripiprazole—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000276	0.000475	CcSEcCtD
Aripiprazole—Pneumonia—Methotrexate—lymphatic system cancer	0.000275	0.000472	CcSEcCtD
Aripiprazole—Vomiting—Bleomycin—lymphatic system cancer	0.000274	0.000471	CcSEcCtD
Aripiprazole—Infestation NOS—Methotrexate—lymphatic system cancer	0.000273	0.000469	CcSEcCtD
Aripiprazole—Infestation—Methotrexate—lymphatic system cancer	0.000273	0.000469	CcSEcCtD
Aripiprazole—Depression—Methotrexate—lymphatic system cancer	0.000272	0.000468	CcSEcCtD
Aripiprazole—Rash—Bleomycin—lymphatic system cancer	0.000272	0.000467	CcSEcCtD
Aripiprazole—Dermatitis—Bleomycin—lymphatic system cancer	0.000272	0.000466	CcSEcCtD
Aripiprazole—Asthenia—Carmustine—lymphatic system cancer	0.00027	0.000464	CcSEcCtD
Aripiprazole—Renal failure—Methotrexate—lymphatic system cancer	0.000269	0.000461	CcSEcCtD
Aripiprazole—Stomatitis—Methotrexate—lymphatic system cancer	0.000266	0.000457	CcSEcCtD
Aripiprazole—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000266	0.000456	CcSEcCtD
Aripiprazole—Hypersensitivity—Vincristine—lymphatic system cancer	0.000265	0.000455	CcSEcCtD
Aripiprazole—Sweating—Methotrexate—lymphatic system cancer	0.000262	0.00045	CcSEcCtD
Aripiprazole—Haematuria—Methotrexate—lymphatic system cancer	0.000261	0.000448	CcSEcCtD
Aripiprazole—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000258	0.000444	CcSEcCtD
Aripiprazole—Epistaxis—Methotrexate—lymphatic system cancer	0.000258	0.000443	CcSEcCtD
Aripiprazole—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000258	0.000443	CcSEcCtD
Aripiprazole—Asthenia—Vincristine—lymphatic system cancer	0.000258	0.000443	CcSEcCtD
Aripiprazole—Diarrhoea—Carmustine—lymphatic system cancer	0.000257	0.000442	CcSEcCtD
Aripiprazole—Nausea—Bleomycin—lymphatic system cancer	0.000256	0.00044	CcSEcCtD
Aripiprazole—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000255	0.000438	CcSEcCtD
Aripiprazole—Asthenia—Mitoxantrone—lymphatic system cancer	0.000251	0.000431	CcSEcCtD
Aripiprazole—Dizziness—Carmustine—lymphatic system cancer	0.000249	0.000427	CcSEcCtD
Aripiprazole—Haemoglobin—Methotrexate—lymphatic system cancer	0.000247	0.000423	CcSEcCtD
Aripiprazole—Diarrhoea—Vincristine—lymphatic system cancer	0.000246	0.000422	CcSEcCtD
Aripiprazole—Haemorrhage—Methotrexate—lymphatic system cancer	0.000245	0.000421	CcSEcCtD
Aripiprazole—Hepatitis—Methotrexate—lymphatic system cancer	0.000245	0.000421	CcSEcCtD
Aripiprazole—Pharyngitis—Methotrexate—lymphatic system cancer	0.000243	0.000418	CcSEcCtD
Aripiprazole—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000242	0.000416	CcSEcCtD
Aripiprazole—Urethral disorder—Methotrexate—lymphatic system cancer	0.00024	0.000413	CcSEcCtD
Aripiprazole—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000239	0.000411	CcSEcCtD
Aripiprazole—Vomiting—Carmustine—lymphatic system cancer	0.000239	0.000411	CcSEcCtD
Aripiprazole—Dizziness—Vincristine—lymphatic system cancer	0.000237	0.000408	CcSEcCtD
Aripiprazole—Rash—Carmustine—lymphatic system cancer	0.000237	0.000407	CcSEcCtD
Aripiprazole—Dermatitis—Carmustine—lymphatic system cancer	0.000237	0.000407	CcSEcCtD
Aripiprazole—Visual impairment—Methotrexate—lymphatic system cancer	0.000236	0.000406	CcSEcCtD
Aripiprazole—Headache—Carmustine—lymphatic system cancer	0.000236	0.000405	CcSEcCtD
Aripiprazole—Eye disorder—Methotrexate—lymphatic system cancer	0.000229	0.000394	CcSEcCtD
Aripiprazole—Tinnitus—Methotrexate—lymphatic system cancer	0.000229	0.000393	CcSEcCtD
Aripiprazole—Vomiting—Vincristine—lymphatic system cancer	0.000228	0.000392	CcSEcCtD
Aripiprazole—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000228	0.000391	CcSEcCtD
Aripiprazole—Rash—Vincristine—lymphatic system cancer	0.000226	0.000389	CcSEcCtD
Aripiprazole—Dermatitis—Vincristine—lymphatic system cancer	0.000226	0.000389	CcSEcCtD
Aripiprazole—Headache—Vincristine—lymphatic system cancer	0.000225	0.000386	CcSEcCtD
Aripiprazole—Nausea—Carmustine—lymphatic system cancer	0.000223	0.000384	CcSEcCtD
Aripiprazole—Angiopathy—Methotrexate—lymphatic system cancer	0.000223	0.000382	CcSEcCtD
Aripiprazole—Vomiting—Mitoxantrone—lymphatic system cancer	0.000222	0.000382	CcSEcCtD
Aripiprazole—Immune system disorder—Methotrexate—lymphatic system cancer	0.000222	0.000381	CcSEcCtD
Aripiprazole—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000221	0.00038	CcSEcCtD
Aripiprazole—Rash—Mitoxantrone—lymphatic system cancer	0.000221	0.000379	CcSEcCtD
Aripiprazole—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00022	0.000378	CcSEcCtD
Aripiprazole—Chills—Methotrexate—lymphatic system cancer	0.00022	0.000378	CcSEcCtD
Aripiprazole—Headache—Mitoxantrone—lymphatic system cancer	0.000219	0.000376	CcSEcCtD
Aripiprazole—Alopecia—Methotrexate—lymphatic system cancer	0.000217	0.000372	CcSEcCtD
Aripiprazole—Mental disorder—Methotrexate—lymphatic system cancer	0.000215	0.000369	CcSEcCtD
Aripiprazole—Erythema—Methotrexate—lymphatic system cancer	0.000214	0.000367	CcSEcCtD
Aripiprazole—Malnutrition—Methotrexate—lymphatic system cancer	0.000214	0.000367	CcSEcCtD
Aripiprazole—Nausea—Vincristine—lymphatic system cancer	0.000213	0.000366	CcSEcCtD
Aripiprazole—Dysgeusia—Methotrexate—lymphatic system cancer	0.000209	0.000359	CcSEcCtD
Aripiprazole—Nausea—Mitoxantrone—lymphatic system cancer	0.000208	0.000357	CcSEcCtD
Aripiprazole—Back pain—Methotrexate—lymphatic system cancer	0.000207	0.000355	CcSEcCtD
Aripiprazole—Vision blurred—Methotrexate—lymphatic system cancer	0.000201	0.000346	CcSEcCtD
Aripiprazole—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000198	0.00034	CcSEcCtD
Aripiprazole—Anaemia—Methotrexate—lymphatic system cancer	0.000197	0.000339	CcSEcCtD
Aripiprazole—Malaise—Methotrexate—lymphatic system cancer	0.000193	0.000331	CcSEcCtD
Aripiprazole—Vertigo—Methotrexate—lymphatic system cancer	0.000192	0.00033	CcSEcCtD
Aripiprazole—Leukopenia—Methotrexate—lymphatic system cancer	0.000191	0.000328	CcSEcCtD
Aripiprazole—Cough—Methotrexate—lymphatic system cancer	0.000186	0.00032	CcSEcCtD
Aripiprazole—Convulsion—Methotrexate—lymphatic system cancer	0.000185	0.000318	CcSEcCtD
Aripiprazole—Chest pain—Methotrexate—lymphatic system cancer	0.000182	0.000312	CcSEcCtD
Aripiprazole—Myalgia—Methotrexate—lymphatic system cancer	0.000182	0.000312	CcSEcCtD
Aripiprazole—Arthralgia—Methotrexate—lymphatic system cancer	0.000182	0.000312	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000181	0.00031	CcSEcCtD
Aripiprazole—Discomfort—Methotrexate—lymphatic system cancer	0.00018	0.000309	CcSEcCtD
Aripiprazole—Confusional state—Methotrexate—lymphatic system cancer	0.000176	0.000302	CcSEcCtD
Aripiprazole—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000174	0.000299	CcSEcCtD
Aripiprazole—Infection—Methotrexate—lymphatic system cancer	0.000173	0.000297	CcSEcCtD
Aripiprazole—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000171	0.000294	CcSEcCtD
Aripiprazole—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000171	0.000293	CcSEcCtD
Aripiprazole—Skin disorder—Methotrexate—lymphatic system cancer	0.000169	0.000291	CcSEcCtD
Aripiprazole—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000168	0.000289	CcSEcCtD
Aripiprazole—Anorexia—Methotrexate—lymphatic system cancer	0.000166	0.000285	CcSEcCtD
Aripiprazole—Hypotension—Methotrexate—lymphatic system cancer	0.000163	0.00028	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000159	0.000273	CcSEcCtD
Aripiprazole—Insomnia—Methotrexate—lymphatic system cancer	0.000158	0.000271	CcSEcCtD
Aripiprazole—Paraesthesia—Methotrexate—lymphatic system cancer	0.000156	0.000269	CcSEcCtD
Aripiprazole—Dyspnoea—Methotrexate—lymphatic system cancer	0.000155	0.000267	CcSEcCtD
Aripiprazole—Somnolence—Methotrexate—lymphatic system cancer	0.000155	0.000266	CcSEcCtD
Aripiprazole—Dyspepsia—Methotrexate—lymphatic system cancer	0.000153	0.000263	CcSEcCtD
Aripiprazole—Decreased appetite—Methotrexate—lymphatic system cancer	0.000151	0.00026	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00015	0.000258	CcSEcCtD
Aripiprazole—Fatigue—Methotrexate—lymphatic system cancer	0.00015	0.000258	CcSEcCtD
Aripiprazole—Pain—Methotrexate—lymphatic system cancer	0.000149	0.000256	CcSEcCtD
Aripiprazole—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000144	0.000247	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000143	0.000245	CcSEcCtD
Aripiprazole—Urticaria—Methotrexate—lymphatic system cancer	0.000138	0.000238	CcSEcCtD
Aripiprazole—Abdominal pain—Methotrexate—lymphatic system cancer	0.000138	0.000237	CcSEcCtD
Aripiprazole—Body temperature increased—Methotrexate—lymphatic system cancer	0.000138	0.000237	CcSEcCtD
Aripiprazole—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000128	0.000221	CcSEcCtD
Aripiprazole—Asthenia—Methotrexate—lymphatic system cancer	0.000125	0.000215	CcSEcCtD
Aripiprazole—Pruritus—Methotrexate—lymphatic system cancer	0.000123	0.000212	CcSEcCtD
Aripiprazole—Diarrhoea—Methotrexate—lymphatic system cancer	0.000119	0.000205	CcSEcCtD
Aripiprazole—Dizziness—Methotrexate—lymphatic system cancer	0.000115	0.000198	CcSEcCtD
Aripiprazole—Vomiting—Methotrexate—lymphatic system cancer	0.000111	0.00019	CcSEcCtD
Aripiprazole—Rash—Methotrexate—lymphatic system cancer	0.00011	0.000189	CcSEcCtD
Aripiprazole—Dermatitis—Methotrexate—lymphatic system cancer	0.00011	0.000189	CcSEcCtD
Aripiprazole—Headache—Methotrexate—lymphatic system cancer	0.000109	0.000188	CcSEcCtD
Aripiprazole—Nausea—Methotrexate—lymphatic system cancer	0.000104	0.000178	CcSEcCtD
